World Health Organization Issues Concern Over Severe Scarcity of Weight-Loss Jabs
Less than a tenth of people that would benefit from obesity jabs including Wegovy are able to get them, warns the global health agency as it publishes its initial recommendations on the medications.
Given over a billion individuals worldwide now living with obesity, it is advocating for broader and more equitable access to GLP-1 medication.
According to projections, more than two billion could be obese by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant hurdles to widespread access to the jabs that can assist patients in reducing considerable body mass, says the organization.
Skinny Jab Supply Crisis
Despite the current most favorable case, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, according to the WHO.
The advice encourages countries and companies to increase access, via approaches such as licensing agreements.
The intellectual property rights on a key compound – the core component of a leading brand – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Drugs Operate
These medications imitate a body's own hormone to slow digestion, reduce hunger and increase feelings of fullness so individuals reduce food intake.
Patients usually start to lose weight in the initial weeks of beginning the once-weekly jabs.
Evidence indicates users may put most of the weight back on after a year of halting the medication, as their usual food cravings return.
To be above a healthy weight raises your risk for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
